Insulet Corp. logo
PODDInsulet Corp.

Annual Revenue

The latest annual annual revenue is $2.71B with a annual period change of +30.73%. Annual revenue is the total sales generated during the company's fiscal year.

PODD Annual Revenue

PODD Annual Revenue Chart

$2.71B

Annual fiscal-year revenue; no daily interpolation.

+926.21% 10Y

Annual Revenue History

DateAnnual Revenue% Change
2025$2.71B+30.73%
2024$2.07B+22.07%
2023$1.70B+30.02%
2022$1.31B+18.79%
2021$1.10B+21.49%
2020$904.40M+22.51%
2019$738.20M+30.93%
2018$563.82M+21.57%
2017$463.77M+26.37%
2016$366.99M+39.07%
2015$263.89M(8.60%)
2014$288.72M+16.85%
2013$247.08M+16.90%
2012$211.37M+38.83%
2011$152.25M+57.02%
2010$96.97M+46.85%
2009$66.03M+83.12%
2008$36.06M+169.66%
2007$13.37M+265.06%
2006$3.66M+7226.00%
2005$50,000-
2004$0-
2003$0-
2002$0-

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy